Papers
3
Total Citations
10
H-Index
3
About
Dr. M. Leitch is a leading clinical researcher in radiation oncology, with a focused expertise in stereotactic body radiation therapy (SBRT) for early-stage breast cancer. Their major contributions center on pioneering dose-escalation protocols for partial breast irradiation, specifically investigating the safety and efficacy of both single-fraction and five-fraction ablative regimens. Dr. Leitch’s work is foundational in the shift toward ultra-hypofractionated, non-invasive treatments that reduce overall treatment time while maintaining tumor control. Their 2023 phase I trial on pre-operative single-fraction ablation for early-stage breast cancer (4 citations) represents a novel approach to neoadjuvant radiotherapy, potentially reshaping surgical and oncologic workflows. Additionally, their 2016 dose-escalation study (3 citations) and 2021 multi-institutional follow-up (3 citations) have provided critical safety and feasibility data, helping to establish stereotactic partial breast irradiation as a viable alternative to standard whole-breast radiation. Though early in citation accumulation, these trials are highly influential within the radiation oncology community, setting the stage for larger phase II/III studies. Dr. Leitch’s work is particularly notable for its translational impact, bridging technical radiation delivery with patient-centered outcomes.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3